RESEARCHERS examining the data on opioids for pain caused by cancer have found surprisingly large gaps in evidence regarding the true benefits of these medicines for cancer pain.
The review challenges the commonly held view that opioids are the most powerful pain relievers.
The University of Sydney-led review highlights there is no 'one size fits all' treatment approach for cancer pain, urging healthcare professionals and patients to carefully weigh up the evidence when deciding on a suitable pain management plan.
Opioid pain relievers are the most common treatment for cancer pain management.
However, the study found very few trials have compared commonly used opioid medicines such as morphine, oxycodone and methadone with placebo.
The study did not find convincing evidence that morphine was better or safer than other opioid medicines for background cancer pain outside of end-of-life care.
This is despite morphine being widely viewed as the 'gold standard treatment' for cancer care.
The review also found that non-steroidal anti-inflammatory drugs including aspirin and diclofenac may be as effective as some opioids for background cancer pain.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Dec 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Dec 23
